Case Study
FROM LIMITATIONS TO EXPANSIONS: HOW PRIORITIZING PATIENTS’ SPEED TO THERAPY DRIVES THERAPY ADOPTION
This EVERSANA COMPLETE Commercialization® case study highlights the importance of prioritizing patients’ speed to therapy to drive product adoption and commercial success. Launching a new therapy is complex and costly, with manufacturers investing an average of $200 million in commercialization before launch, yet only about one-third of therapies meet expectations. Despite extensive planning, unforeseen barriers can delay patient access and limit uptake. The case demonstrates how focusing on reducing access obstacles, accelerating treatment initiation, and improving the patient experience can enhance therapy adoption and market performance. By aligning commercialization strategies around patient needs and creating more efficient pathways to treatment, manufacturers can overcome launch chal
